In the context of the search for predictive biomarkers, the most useful are proteins that modulate the response to targeted therapy, and their expression changes depending on the degree of sensitivity/resistance of tumor cells to BRAF/MEK inhibitors. This evidence concerns the gene BRAF and neoplasm.